Non-tuberculous mycobacterial infections—A neglected and emerging problem

Ahmed, Imran; Tiberi, Simon; Farooqi, Joveria; Jabeen, Kauser; Yeboah-Manu, Dorothy; Migliori, Giovanni Battista; Hasan, Rumina

doi:10.1016/j.ijid.2020.02.022

Cited by 48 publications

(27 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Non-tuberculous mycobacterial (NTM) disease has been steadily increasing globally owing to a growing population of immunocompromised, complex surgical procedures, as well as increased diagnostic capabilities [ 4 ]. M .…”

Section: Discussionmentioning

confidence: 99%

Mycobacterium farcinogenes osteomyelitis of the proximal tibia: A case report

Farsi

Adawi

Tahir

et al. 2021

IDCases

View full text Add to dashboard Cite

Non-tuberculous mycobacteria (NTM) are an unusual cause of osteomyelitis. Mycobacterium farcinogenes is an uncommon cause of human disease. We describe here the first case of M. farcinogenes osteomyelitis in a 49-year-old man who underwent left knee anterior cruciate ligament and medial meniscal repair which was complicated by recurrent septic arthritis and surgical site infection. As a consequence, he underwent multiple surgical debridements. Ultimately, left proximal tibial osteomyelitis was diagnosed and M. farcinogenes was recovered from the tissue biopsy culture. Clinical improvement was achieved following surgical removal of the prosthesis along with prolonged combination antimicrobial therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Mycobacterium farcinogenes osteomyelitis of the proximal tibia: A case report

Farsi

Adawi

Tahir

et al. 2021

IDCases

View full text Add to dashboard Cite

show abstract

“…Specific mycobacterial cultures need to be requested to make the diagnosis but hospital physicians and general practitioners are not necessarily familiar with NTM disease. This can cause considerable delays in diagnosis:the median time from symptom onset to diagnosis has been estimated to be at least two years (Ahmed et al, 2020). Current guidelines recommend tests for NTM infection in patients with bronchiectasis (Haworth et al, 2017), but this is performed in less than a fifth of patients (Finch et al, 2019).…”

Section: Making a Diagnosis And Planning Medical Treatmentmentioning

confidence: 99%

Non tuberculous mycobacteria pulmonary disease: patients and clinicians working together to improve the evidence base for care

Lipman

Kunst

Loebinger

et al. 2021

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Non-tuberculous mycobacterial pulmonary disease is on the rise globally. It is often missed, and causes significant morbidity and even mortality. Here, members of a clinical research network and a patient support group discuss some of the current key issues in NTM management.In addition to the need for research into epidemiology, immunology and treatment, we recommend greater use of patient and clinician networks to: (i) educate primary and secondary care clinicians to develop a high index of suspicion when investigating and treating at risk populations. (ii) promote a multidisciplinary team. (iii) promote shared patient-clinician decision making throughout care. (iv) incorporate use of patient self-report measures to assess progress and outcomes. (v) increase education of patients on their illness and its management. (vi) recruit patients into research projects and registries to improve the clinical evidence base. (vii) increase co-production of research with key stakeholders such as patients and their families, using expert patients and patient groups. (viii) understand more about the psychological, social and economic consequences of the disease.

show abstract

“…cystic fibrosis (Park and Olivier 2015 ), are affected. Non-tubercular mycobacteria not only cause lung tissue infections (Weiss and Glassroth 2012 ; Wassilew et al 2016 ), but also affect the skin, soft tissue and the central nervous system (Ahmed et al 2020 ). Development of new antibiotics is needed to overcome drug resistance and to provide new options for treatment (Wu et al 2018 ).…”

Section: Introductionmentioning

confidence: 99%

Racemization-free synthesis of Nα-2-thiophenoyl-phenylalanine-2-morpholinoanilide enantiomers and their antimycobacterial activity

et al. 2021

View full text Add to dashboard Cite

Nα-2-thiophenoyl-d-phenylalanine-2-morpholinoanilide (MMV688845, IUPAC: N-(1-((2-morpholinophenyl)amino)-1-oxo-3-phenylpropan-2-yl)thiophene-2-carboxamide) from the Pathogen Box® library (Medicines for Malaria Ventures, MMV) is a promising lead compound for antimycobacterial drug development. Two straightforward synthetic routes to the title compound starting from phenylalanine or its Boc-protected derivative are reported. Employing Boc-phenylalanine as starting material and the T3P® and PyBOP® amide coupling reagents enables racemization-free synthesis, avoiding the need for subsequent separation of the enantiomers. The crystal structure of the racemic counterpart gives insight into the molecular structure and hydrogen bonding interactions in the solid state. The R-enantiomer of the title compound (derived from d-phenylalanine) exhibits activity against non-pathogenic and pathogenic mycobacterial strains, whereas the S-enantiomer is inactive. Neither of the enantiomers and the racemate of the title compound shows cytotoxicity against various mammalian cells.

show abstract

Non-tuberculous mycobacterial infections—A neglected and emerging problem

Cited by 48 publications

References 28 publications

Mycobacterium farcinogenes osteomyelitis of the proximal tibia: A case report

Mycobacterium farcinogenes osteomyelitis of the proximal tibia: A case report

Non tuberculous mycobacteria pulmonary disease: patients and clinicians working together to improve the evidence base for care

Racemization-free synthesis of Nα-2-thiophenoyl-phenylalanine-2-morpholinoanilide enantiomers and their antimycobacterial activity

Contact Info

Product

Resources

About